CVRx commends Christus Trinity Mother Frances on 10th Barostim heart failure implant milestone

CVRx commends Christus Trinity Mother Frances on 10th Barostim heart failure implant milestone
CVRx notes tenth Barostim implant

CVRx announced that Christus Trinity Mother Frances has reached its tenth successful Barostim implant for patients with heart failure.

This milestone highlights the dedication of Dr. Todd Bengtson, David McCaskill, NP, Emily Evans, NP, and their team in providing advanced therapy options. The Barostim neuromodulation treatment is designed to improve outcomes for individuals living with heart failure, signaling continued momentum in medical technology adoption.

CVRx recently added Michael Dale to its board to draw on his leadership experience in medical devices, according to a prior announcement from the company. The company is also advancing clinical integration of Barostim, hosting a symposium at AAHFN2026 to support adoption among advanced practice providers at a key industry event. These initiatives come as CVRx continues to expand the reach of its Barostim therapy.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.